Publications

Export 4 results:
Sort by: Author Title Type [ Year (Desc)]
2019
Yeung, A. W. K., N. T. Tzvetkov, O. S. El-Tawil, S. G. Bungǎu, M. M. Abdel-Daim, and A. G. Atanasov, "Antioxidants: Scientific Literature Landscape Analysis (Review article)", Oxidative Medicine and Cellular Longevity, vol. 2019, pp. 1-11, 2019.
Bakr, A. F., S. S. Abdelgayed, O. S. El-Tawil, and A. M. Bakeer, "Assessment of Ginger Extract and Ginger Nanoparticles Protective Activity against Acetaminophen-Induced Hepatotoxicity and Nephrotoxicity in Rats", Pakistan Veterinary Journal, vol. 060, pp. 1-8, 2019.
application/pdf iconalaa_phd_paper_2019.pdf
Essa, S. S., E. M. El-Saied, O. S. El-Tawil, I. M. Gamal, and S. A. S. El-Rahman, "Nanoparticles of zinc oxide defeat chlorpyrifos-induced immunotoxic effects and histopathological alterations", Veterinary World, vol. 12, issue March, pp. 440-448, 2019.
2017
Daghestani, M. H., M. E. Selim, Y. M. Abd-Elhakim, E. N. Said, N. A. E. El-Hameed, S. R. Khalil, and O. S. El-Tawil, "The role of apitoxin in alleviating propionic acid-induced neurobehavioral impairments in rat pups: The expression pattern of Reelin gene.", Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, vol. 93, pp. 48-56, 2017 Sep. Abstract

The efficacy of apitoxin (bee venom; BV) in ameliorating propionic acid (PPA) -induced neurobehavioral impacts was studied. Sixty rat pups were enrolled in a split litter design to six groups: a control group, a PPA-treated group, a BV-treated group, a BV/PPA protective group, a PPA/BV therapeutic group, and a BV/PPA/BV protective and therapeutic group. Exploratory, social, locomotor, and repetitive/stereotype-like activities were assessed and prosocial, empathy, and acquired behavior were evaluated. Levels of neurotransmitter including serotonin, dopamine, and gamma-aminobutyric acid (GABA) were determined and a quantitative analysis of Reelin gene expression was performed. PPA treatment induced several behavioral alterations, as reduced exploratory activity and social behaviors, increased repetitive/stereotypic behaviors, and hyperactivity. In addition, a marked decline of neurotransmitters and down-regulation of Reelin mRNA expression were observed. BV exhibited high efficiency in ameliorating the PPA-induced neurobehavioral alterations, particularly when applied both before and after PPA administration. Overall, the results implied that BV has merit as a candidate therapeutic treatment to alleviate PPA-induced neurobehavioral disorders.